Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE StudyE. Trovato, Antonio Costanzo, Massimiliano Scalvenzi et al.|Dermatology and Therapy|2026Cited by 1